The influence of oxytocin on automatic imitation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-002925-30-BE

Enrollment

Unknown

Registered

2012-08-30

Start date

2012-09-21

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigate the influence of oxytocin on automatic imitation

Interventions

Trade Name: Syntocinon neusspray Product Name: Oxytocine Pharmaceutical Form: Nasal spray INN or Proposed INN: Oxytocin CAS Number: 50-56-6 Current Sponsor code: oxytocin Other descriptive name: OXYTO

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Male - Non-smoker - 18 to 40 years old Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Female, - Pacemaker, deep brain stimulation electrodes, or other stimulation equipment - Abnormal neurological background (brain surgeries, migraine, epilepsy, alcoholism) - Epilepsy in the near family - Chronical diseases which require constant medication (asthma, hypertension, diabetes - Intake of medication 24h before the experiment - Intake of alcohol or caffeine 2h before the experiment - Sleep deprivation 24h before the experiment

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the influence of oxytocin on automatic imitation ;Secondary Objective: Not applicable;Primary end point(s): Measurement of the reaction time while performing an imitation-inhibition task and a cognitive control task ;Timepoint(s) of evaluation of this end point: 45 minutes after administration of oxytocin or placebo	—

Secondary

Measure	Time frame
Secondary end point(s): Verifying side-effects;Timepoint(s) of evaluation of this end point: After the imitation-inhibition task and the cognitive control task	—

Countries

Belgium

Contacts

Public ContactTrial Bureau

University Ghent

Trialbureau@uzgent.be3293320500

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026